Page 133 - 《中国药房》2025年1期

open-label，randomised，active-controlled，phase 3a trial tes （SUSTAIN 11）：a randomized，open-label，multina‐
[J]. Lancet Diabetes Endocrinol，2020，8（5）：392-406. tional，phase 3b trial[J]. Diabetes Obes Metab，2022，24
[18] SORLI C，HARASHIMA S I，TSOUKAS G M，et al. Effi‐ （9）：1788-1799.
cacy and safety of once-weekly semaglutide monotherapy [27] SEINO Y，TERAUCHI Y，OSONOI T，et al. Safety and
versus placebo in patients with type 2 diabetes （SUSTAIN efficacy of semaglutide once weekly vs sitagliptin once
1） ：a double-blind，randomised，placebo-controlled， daily，both as monotherapy in Japanese people with type 2
parallel-group，multinational，multicentre phase 3a trial[J]. diabetes[J]. Diabetes Obes Metab，2018，20（2）：378-388.
Lancet Diabetes Endocrinol，2017，5（4）：251-260. [28] JI L N，DONG X L，LI Y M，et al. Efficacy and safety of
[19] AHRÉN B，MASMIQUEL L，KUMAR H，et al. Efficacy once-weekly semaglutide versus once-daily sitagliptin as
and safety of once-weekly semaglutide versus once-daily add-on to metformin in patients with type 2 diabetes in
sitagliptin as an add-on to metformin，thiazolidinediones， SUSTAIN China：a 30-week，double-blind，phase 3a，ran‐
or both，in patients with type 2 diabetes （SUSTAIN 2）：a domized trial[J]. Diabetes Obes Metab，2021，23（2）：
56-week，double-blind，phase 3a，randomised trial[J]. Lan‐ 404-414.
cet Diabetes Endocrinol，2017，5（5）：341-354. [29] DAVIES M，FERCH L，JEPPESEN O K，et al. Semaglu‐
[20] AHMANN A J，CAPEHORN M，CHARPENTIER G，et al. tide 2.4 mg once a week in adults with overweight or obe‐
Efficacy and safety of once-weekly semaglutide versus sity，and type 2 diabetes （STEP 2）：a randomised，double-
exenatide ER in subjects with type 2 diabetes （SUSTAIN 3）： blind，double-dummy，placebo-controlled，phase 3 trial[J].
a 56-week，open-label，randomized clinical trial[J]. Diabetes Lancet，2021，397（10278）：971-984.
Care，2018，41（2）：258-266. [30] NACHNANI J S，BULCHANDANI D G，NOOKALA A，
[21] ARODA V R，BAIN S C，CARIOU B，et al. Efficacy and et al. Biochemical and histological effects of exendin-4
safety of once-weekly semaglutide versus once-daily insu‐ （exenatide） on the rat pancreas[J]. Diabetologia，2010，53
lin glargine as add-on to metformin （with or without sulfony- （1）：153-159.
lureas） in insulin-naive patients with type 2 diabetes [31] ROMLEY J A，GOLDMAN D P，SOLOMON M，et al.
（SUSTAIN 4）：a randomised，open-label，parallel-group， Exenatide therapy and the risk of pancreatitis and pancre‐
multicentre，multinational，phase 3a trial[J]. Lancet Diabe‐ atic cancer in a privately insured population[J]. Diabetes
tes Endocrinol，2017，5（5）：355-366. Technol Ther，2012，14（10）：904-911.
[22] RODBARD H W，LINGVAY I，REED J，et al. Semaglu‐ [32] DORE D D，SEEGER J D，CHAN K A. Incidence of
tide added to basal insulin in type 2 diabetes （SUSTAIN 5）： health insurance claims for thyroid neoplasm and pancreatic
a randomized，controlled trial[J]. J Clin Endocrinol malignancy in association with exenatide：signal refine‐
Metab，2018，103（6）：2291-2301. ment using active safety surveillance[J]. Ther Adv Drug
[23] PRATLEY R E，ARODA V R，LINGVAY I，et al. Sema‐ Saf，2012，3（4）：157-164.
glutide versus dulaglutide once weekly in patients with [33] ABRAHAMI D，YIN H，YU O H Y，et al. Incretin-based
type 2 diabetes （SUSTAIN 7）：a randomised，open-label， drugs and the incidence of colorectal cancer in patients
phase 3b trial[J]. Lancet Diabetes Endocrinol，2018，6（4）： with type 2 diabetes[J]. Epidemiology，2018，29（2）：
275-286. 246-253.
[24] LINGVAY I，CATARIG A M，FRIAS J P，et al. Efficacy [34] NAUCK M A，JENSEN T J，ROSENKILDE C，et al. Neo‐
and safety of once-weekly semaglutide versus daily cana‐ plasms reported with liraglutide or placebo in people with
gliflozin as add-on to metformin in patients with type 2 type 2 diabetes：results from the LEADER randomized
diabetes （SUSTAIN 8）：a double-blind，phase 3b，ran‐ trial[J]. Diabetes Care，2018，41（8）：1663-1671.
domised controlled trial[J]. Lancet Diabetes Endocrinol， [35] IWAYA C，NOMIYAMA T，KOMATSU S，et al. Exendin-4，
2019，7（11）：834-844. a glucagon-like peptide-1 receptor agonist，attenuates
[25] ZINMAN B，BHOSEKAR V，BUSCH R，et al. Semaglu‐ breast cancer growth by inhibiting NF- κB activation[J].
tide once weekly as add-on to SGLT-2 inhibitor therapy in Endocrinology，2017，158（12）：4218-4232.
type 2 diabetes （SUSTAIN 9）：a randomised，placebo- [36] TOKI S，GOLENIEWSKA K，REISS S，et al. Glucagon-
controlled trial[J]. Lancet Diabetes Endocrinol，2019，7 like peptide 1 signaling inhibits allergen-induced lung IL-33
（5）：356-367. release and reduces group 2 innate lymphoid cell cytokine
[26] KELLERER M，KALTOFT M S，LAWSON J，et al. Ef‐ production in vivo[J]. J Allergy Clin Immunol，2018，142
fect of once-weekly semaglutide versus thrice-daily insu‐ （5）：1515-1528.
lin aspart，both as add-on to metformin and optimized in‐ （收稿日期：2024-07-21 修回日期：2024-12-01）
sulin glargine treatment in participants with type 2 diabe‐ （编辑：刘明伟）

中国药房 2025年第36卷第1期 China Pharmacy 2025 Vol. 36 No. 1 · 123 ·